BG
ACOR

BlackRock Group’s Acorda Therapeutics ACOR Stock Holding History

BlackRock Group’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2.41M Buy
1,068
+281
+36% +$668K ﹤0.01% 1642
2016
Q3 		$1.97M Buy
787
+58
+8% +$173K ﹤0.01% 1638
2016
Q2 		$2.23M Buy
729
+10
+1% +$32.5K ﹤0.01% 1493
2016
Q1 		$2.28M Buy
719
+55
+8% +$228K ﹤0.01% 1459
2015
Q4 		$3.41M Sell
664
-26
-4% -$114K ﹤0.01% 1229
2015
Q3 		$2.19M Sell
690
-35
-5% -$136K ﹤0.01% 1443
2015
Q2 		$2.9M Buy
725
+79
+12% +$305K ﹤0.01% 1364
2015
Q1 		$2.58M Buy
646
+46
+8% +$211K ﹤0.01% 1367
2014
Q4 		$2.94M Sell
600
-41
-6% -$176K ﹤0.01% 1316
2014
Q3 		$2.6M Buy
641
+16
+3% +$60K ﹤0.01% 1322
2014
Q2 		$2.53M Sell
625
-1,214
-66% -$4.95M ﹤0.01% 1361
2014
Q1 		$8.37M Buy
1,839
+421
+30% +$1.7M 0.01% 964
2013
Q4 		$4.97M Sell
1,418
-1,377
-49% -$5.37M ﹤0.01% 1087
2013
Q3 		$11.5M Sell
2,795
-42
-1% -$181K 0.01% 887
2013
Q2 		$11.2M Buy
+2,837
New +$11.7M 0.01% 832

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BlackRock Group's ACOR Position: Q4 2016 in Review

BlackRock Group increased its Acorda Therapeutics (ACOR) stake by 36% in Q4 2016, buying an estimated $668K and bringing the position to 1,068 shares worth $2.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1642.

BlackRock Group first reported a position in ACOR in Q2 2013 and has held it in 15 quarters since. The position peaked at $11.5M in Q3 2013. 175 funds tracked by Wall St. Rank hold ACOR as of Q4 2016.

  • BlackRock Group held 1,068 shares of Acorda Therapeutics worth $2.41M as of Q4 2016.
  • BlackRock Group bought 281 Acorda Therapeutics shares in Q4 2016, an estimated $668K.
  • Acorda Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1642 holding.
  • BlackRock Group first reported a position in Acorda Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Acorda Therapeutics position peaked at $11.5M in Q3 2013.
  • 175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.